{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:15:18Z","timestamp":1792181718439,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.canlet.2023.216107","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T08:34:48Z","timestamp":1677227688000},"page":"216107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Hybrid extracellular vesicles for drug delivery"],"prefix":"10.1016","volume":"558","author":[{"given":"Coline","family":"Ducrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Madec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Volatron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-101X","authenticated-orcid":false,"given":"Max","family":"Piffoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216107_bib1","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Y\u00e1\u00f1ez-M\u00f3","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.canlet.2023.216107_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2023.216107_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113972","article-title":"Engineering and loading therapeutic extracellular vesicles for clinical translation: A data reporting frame for comparability","volume":"178","author":"Piffoux","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2023.216107_bib4","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-018-0211-z","article-title":"Therapeutic potential of engineered extracellular vesicles","volume":"20","author":"Mentkowski","year":"2018","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.canlet.2023.216107_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2009.05.036","article-title":"Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties","volume":"139","author":"Zucker","year":"2009","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2023.216107_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.04.012","article-title":"A call for the standardised reporting of factors affecting the exogenous loading of extracellular Vesicles with therapeutic cargos","volume":"173","author":"Rankin-Turner","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.canlet.2023.216107_bib7","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v2i0.19861","article-title":"How pure are your vesicles?","volume":"2","author":"Webber","year":"2013","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.canlet.2023.216107_bib8","doi-asserted-by":"crossref","unstructured":"L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, M.J.A. Wood, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol. (2011). 29, 341\u2013345 (2011). doi:10.1038\/nbt.1807.","DOI":"10.1038\/nbt.1807"},{"key":"10.1016\/j.canlet.2023.216107_bib9","doi-asserted-by":"crossref","unstructured":"S.A.A. Kooijmans, S. Stremersch, K. Braeckmans, S.C. de Smedt, A. Hendrix, M.J.A. Wood, et al., Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles, J. Contr. Release (2013). 28;172(1):229-238. doi: 10.1016\/j.jconrel.2013.08.014. Epub 2013 Aug 29.","DOI":"10.1016\/j.jconrel.2013.08.014"},{"issue":"4","key":"10.1016\/j.canlet.2023.216107_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201700611","article-title":"Exosome\u2013liposome hybrid nanoparticles deliver CRISPR\/Cas9 system in MSCs","volume":"5","author":"Lin","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2023.216107_bib11","series-title":"(54) (71) (72) (73) (21) (22) (86) (60) HYBRIDOSOMES, COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THER PRODUCTION AND USES THEREOF","author":"Beer","year":"2016"},{"key":"10.1016\/j.canlet.2023.216107_bib12","doi-asserted-by":"crossref","unstructured":"M. Piffoux, A.K.A. Silva, C. Wilhelm, F. Gazeau, D. Tareste, Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems, ACS Nano (2018). 12(7):6830-6842. doi: 10.1021\/acsnano.8b02053. Epub 2018 Jul 10.","DOI":"10.1021\/acsnano.8b02053"},{"key":"10.1016\/j.canlet.2023.216107_bib13","article-title":"Engineering hybrid exosomes by membrane fusion with liposomes","volume":"6","author":"Sato","year":"2016","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.canlet.2023.216107_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202000515","article-title":"Thermosensitive exosome\u2013liposome hybrid nanoparticle-mediated chemoimmunotherapy for improved treatment of metastatic peritoneal cancer","volume":"7","author":"Lv","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2023.216107_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.actbio.2019.05.054","article-title":"Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery","volume":"94","author":"Rayamajhi","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.canlet.2023.216107_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118802","article-title":"Engineered extracellular vesicles with synthetic lipids via membrane fusion to establish efficient gene delivery","volume":"573","author":"Jhan","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.canlet.2023.216107_bib17","first-page":"271","article-title":"Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis","author":"Sun","year":"2021","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.canlet.2023.216107_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101202","article-title":"Functional siRNA delivery by extracellular vesicle\u2013liposome hybrid nanoparticles","volume":"11","author":"Evers","year":"2022","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"10.1016\/j.canlet.2023.216107_bib19","doi-asserted-by":"crossref","DOI":"10.1039\/C9BM01766F","article-title":"Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma","volume":"8","author":"Molinaro","year":"2020","journal-title":"Biomater. Sci."},{"issue":"19","key":"10.1016\/j.canlet.2023.216107_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202100794","article-title":"Biomimetic liposome with surface-bound elastase for enhanced tumor penetration and chemo-immumotherapy","volume":"10","author":"Li","year":"2021","journal-title":"Adv Healthc Mater"},{"issue":"5","key":"10.1016\/j.canlet.2023.216107_bib21","doi-asserted-by":"crossref","DOI":"10.1039\/C8SC03224F","article-title":"Artificial chimeric exosomes for anti-phagocytosis and targeted cancer therapy","volume":"10","author":"Zhang","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.canlet.2023.216107_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2016.01.009","article-title":"PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time","volume":"224","author":"Kooijmans","year":"2016","journal-title":"J. Contr. Release"},{"issue":"6","key":"10.1016\/j.canlet.2023.216107_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2018.03.019","article-title":"Hydrophobicity of lipid-conjugated siRNAs predicts productive loading to small extracellular vesicles","volume":"26","author":"Biscans","year":"2018","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.canlet.2023.216107_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2016.126","article-title":"Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing","volume":"24","author":"Didiot","year":"2016","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.canlet.2023.216107_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj7002","article-title":"Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity","volume":"8","author":"Kamerkar","year":"2022","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.canlet.2023.216107_bib26","article-title":"Functional delivery of lipid-conjugated siRNA by extracellular vesicles","volume":"25","author":"O'Loughlin","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2023.216107_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s00249-006-0097-z","article-title":"PEG as a tool to gain insight into membrane fusion","volume":"vol. 36","author":"Lentz","year":"2007","journal-title":"Eur. Biophys. J."},{"issue":"12","key":"10.1016\/j.canlet.2023.216107_bib28","doi-asserted-by":"crossref","DOI":"10.1021\/acsabm.1c00804","article-title":"Polyethylene glycol-mediated fusion of extracellular vesicles with cationic liposomes for the design of hybrid delivery systems","volume":"4","author":"Mukherjee","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"issue":"1","key":"10.1016\/j.canlet.2023.216107_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S0005-2736(01)00462-X","article-title":"Differential destabilization of membranes by tryptophan and phenylalanine during freezing: the roles of lipid composition and membrane fusion","volume":"1561","author":"Popova","year":"2002","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"38","key":"10.1016\/j.canlet.2023.216107_bib30","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M109.010835","article-title":"Binding and cleavage specificities of human Argonaute 2","volume":"284","author":"Lima","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.canlet.2023.216107_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-02004-5","article-title":"ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance","volume":"4","author":"Jang","year":"2021","journal-title":"Commun. Biol."},{"issue":"5","key":"10.1016\/j.canlet.2023.216107_bib32","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.ymthe.2021.01.020","article-title":"A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties","volume":"29","author":"Dooley","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2023.216107_bib33","first-page":"A425.2","article-title":"709 exosome surface display of IL-12 Results in tumor-retained pharmacology with superior potency and limited systemic exposure","author":"Lewis","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.canlet.2023.216107_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2012.180","article-title":"Systemically injected exosomes targeted to EGFR deliver antitumor microrna to breast cancer cells","volume":"21","author":"Ohno","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2023.216107_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12085","article-title":"Biodistribution of extracellular vesicles following administration into animals: a systematic review","volume":"10","author":"Kang","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.canlet.2023.216107_bib36","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.26316","article-title":"Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting","volume":"4","author":"Wiklander","year":"2015","journal-title":"J. Extracell. Vesicles"},{"issue":"7","key":"10.1016\/j.canlet.2023.216107_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2013.11.083","article-title":"A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy","volume":"35","author":"Tian","year":"2014","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.canlet.2023.216107_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"issue":"13_Supplement","key":"10.1016\/j.canlet.2023.216107_bib39","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT114","article-title":"Abstract CT114: randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, PK and PD of exoIL-12 - a novel engineered exosome therapeutic candidate","volume":"81","author":"Mitchell","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216107_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-3-10","article-title":"Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase 1 clinical trial","volume":"3","author":"Escudier","year":"2005","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.canlet.2023.216107_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1071008","article-title":"Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC","volume":"5","author":"Besse","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2023.216107_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114001","article-title":"Development of extracellular vesicle-based medicinal products: a position paper of the group \u201cextracellular vesicle translation to clinicaL perspectiVEs \u2013 EVOLVE France","volume":"vol. 179","author":"Silva","year":"2021","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:08:26Z","timestamp":1759594106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":42,"alternative-id":["S0304383523000587"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216107","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hybrid extracellular vesicles for drug delivery","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216107"}}